Market Overview
| Study Period | 2019 - 2030 |
|---|---|
| Base Year For Estimation | 2024 |
| Forecast Data Period | 2025 - 2030 |
| Market Size (2025) | USD 158.01 Million |
| Market Size (2030) | USD 190.41 Million |
| Growth Rate (2025 - 2030) | 3.80% CAGR |
| Market Concentration | Medium |
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. | |
Thailand Diabetes Drugs Market Analysis by Mordor Intelligence
The Thailand Diabetes Drugs Market size is estimated at USD 158.01 million in 2025, and is expected to reach USD 190.41 million by 2030, at a CAGR of 3.8% during the forecast period (2025-2030).
The healthcare system was significantly disturbed and pressured during each phase of rapid COVID-19 infection. Several countries, notably the Thai government, introduced home isolation or a home quarantine program to avert healthcare collapse and to ameliorate inadequate healthcare resources. Between July 2021 and October 2021, COVID-19 illness cases in Thailand increased to around 20,000-25,000 cases per day, posing difficulty in treating COVID-19 infection in hospitals. Previous research revealed the viability of a COVID-19 home monitoring program employing telemedicine to reduce the gap in treatment during a healthcare worker shortage in multiple countries. These programs monitored the intensity of symptoms and informed patients to seek additional treatment if necessary.
During COVID-19, there was a shortage of hospital capacity, and a home isolation system was set up. Thailand's government introduced diabetes self-management education and support (DSMES, glycemic management via telemedicine, and outcomes in home-isolated patients with COVID-19 infection. In August 2022, The National Research Council of Thailand (NRCT) introduced a breathalyzer prototype that can detect those infected with COVID-19 with 97% accuracy.
In terms of medicines, the insulin category commands a sizable market share. Over 100 million people worldwide use insulin, including all persons with Type 1 diabetes and 10% to 25% of people with Type 2 diabetes. Insulin production is extremely sophisticated, and only a few manufacturers are on the market. As a result, there is fierce rivalry among these producers, who continually strive to satisfy patients' demands by providing the highest-quality insulin.
Thailand Diabetes Drugs Market Trends and Insights
Oral-Anti Diabetes Drugs Segment is Having the Highest Market Share in Current Year
The Oral-Anti Diabetes Drugs segment is expected to increase with a CAGR of over 5 % during the forecast period, mainly due to the demand from the Type-1 diabetes population, which was more than 0.4 million by the end 2022.
Thailand's government, during COVID-19, provided medical supplies, including glucometers, blood glucose test strips, lancets, and urine test strips that were donated or purchased using donated funds. The supplies were stocked at a central location and distributed by volunteers, utilizing same-day commercial delivery services. Disposable prefilled insulin pens, both long-acting and short-acting analogs, were chosen instead of insulin vials to reduce administration errors, particularly in insulin-naïve patients. Insulin pens were kept at a medical clinic and distributed in a temperature-controlled container by a same-day delivery service.
Insulin therapy is the most potent hypoglycaemic medication currently available for diabetes treatment; however, the potency of insulin deteriorates if it is stored under improper conditions. In Thailand, NCDs, including diabetes, account for more than 70% of all deaths. Obesity leads to a more than seven times increase in the risk of developing type 2 diabetes, while being overweight increases the risk by three times.
Through Thailand's government encouragement, the usage of Management Devices increased over the forecast period.
Increasing Diabetes population in Thailand
The World Health Organization (WHO) estimates that in 2021, around 11% of the total health expenditure in Thailand is allocated to diabetes care, comparable to other countries in the region. By 2030, this figure is expected to grow by 41%, effectively doubling the societal burden of diabetes. In Thailand, around 4.8 million people have diabetes, and only 272 endocrinologists (or specialists) are available. In Thailand, three out of five people with diabetes who receive care do not achieve the recommended treatment targets.
Thus, the above factors are expected to drive the market growth over the forecast period.
Competitive Landscape
The diabetes drugs market is Semi consolidated, with few significant generic players. A few major players, like Novo-Nordisk, Sanofi, AstraZeneca, and Bristol Myers Squibb, dominate the insulin drugs and Sglt-2 drugs market. The market for oral drugs, like Sulfonylureas and Meglitinides, comprises more generic players. The intensity of competition among the players is high, as each player is striving to develop new drugs and offer them at competitive pricing. Furthermore, players are tapping into new markets to increase their market shares, especially in emerging economies where the demand is very high compared to the supply.
Thailand Diabetes Drugs Industry Leaders
Eli Lilly
Boehringer Ingelheim
Astrazeneca
Sanofi
NovoNordisk
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competitors?
Download PDF
Recent Industry Developments
- March 2023: Daewoong Pharmaceutical intends to expedite its expansion into the ASEAN countries. This will commence with the submission of NDA for Envlo in Indonesia, Philippines, and Thailand. Additionally, they have outlined their strategy to facilitate entry into other nations including China, Saudi Arabia, and Russia. Their goal is to establish a presence in 15 countries by 2025 and further expand to 50 countries by 2030, solidifying their position as the leading pharmaceutical company in the nation.
- August 2022: Google Launched AI Project in Thailand to screen for diabetic eye disease, to show Social benefits of AI technologies.
Thailand Diabetes Drugs Market Report Scope
Diabetes or diabetes mellitus describes a group of metabolic disorders characterized by a high blood sugar level in a person. With diabetes, the body either does not produce enough insulin or the body's cells do not respond properly to insulin, or both. Thailand's diabetes drugs market witnessed usd 532 million in the current year and is anticipated to register a cagr of over 1% during the forecast period. Thailand's diabetes drugs market is segmented into drugs (oral anti-diabetic drugs, insulin, non-insulin injectable drugs, and combination drugs). The report offers the market size in value terms in usd for all the abovementioned segments.
Oral Anti-diabetic drugs
| Biguanides | Metformin |
| Alpha-Glucosidase Inhibitors | Alpha-Glucosidase Inhibitors |
| Dopamine D2 receptor agonist | Bromocriptin |
| SGLT-2 inhibitors | Invokana (Canagliflozin) |
| Jardiance (Empagliflozin) | |
| Farxiga/Forxiga (Dapagliflozin) | |
| Suglat (Ipragliflozin) | |
| DPP-4 inhibitors | Onglyza (Saxagliptin) |
| Tradjenta (Linagliptin) | |
| Vipidia/Nesina(Alogliptin) | |
| Galvus (Vildagliptin) | |
| Sulfonylureas | Sulfonylureas |
| Meglitinides | Meglitinides |
Insulins
| Basal or Long Acting Insulins | Lantus (Insulin Glargine) |
| Levemir (Insulin Detemir) | |
| Toujeo (Insulin Glargine) | |
| Tresiba (Insulin Degludec) | |
| Basaglar (Insulin Glargine) | |
| Bolus or Fast Acting Insulins | NovoRapid/Novolog (Insulin Aspart) |
| Humalog (Insulin Lispro) | |
| Apidra (Insulin Glulisine) | |
| Traditional Human Insulins | Novolin/Actrapid/Insulatard |
| Humulin | |
| Insuman | |
| Biosimilar Insulins | Insulin Glargine Biosimilars |
| Human Insulin Biosimilars |
Combination drugs
| Insulin combinations | NovoMix (Biphasic Insulin Aspart) |
| Ryzodeg (Insulin Degludec and Insulin Aspart) | |
| Xultophy (Insulin Degludec and Liraglutide) | |
| Oral Combinations | Janumet (Sitagliptin and Metformin) |
Non-Insulin Injectable drugs
| GLP-1 receptor agonists | Victoza (Liraglutide) |
| Byetta (Exenatide) | |
| Bydureon (Exenatide) | |
| Trulicity (Dulaglutide) | |
| Lyxumia (Lixisenatide) | |
| Amylin Analogue | Symlin (Pramlintide) |
| Oral Anti-diabetic drugs | Biguanides | Metformin |
| Alpha-Glucosidase Inhibitors | Alpha-Glucosidase Inhibitors | |
| Dopamine D2 receptor agonist | Bromocriptin | |
| SGLT-2 inhibitors | Invokana (Canagliflozin) | |
| Jardiance (Empagliflozin) | ||
| Farxiga/Forxiga (Dapagliflozin) | ||
| Suglat (Ipragliflozin) | ||
| DPP-4 inhibitors | Onglyza (Saxagliptin) | |
| Tradjenta (Linagliptin) | ||
| Vipidia/Nesina(Alogliptin) | ||
| Galvus (Vildagliptin) | ||
| Sulfonylureas | Sulfonylureas | |
| Meglitinides | Meglitinides | |
| Insulins | Basal or Long Acting Insulins | Lantus (Insulin Glargine) |
| Levemir (Insulin Detemir) | ||
| Toujeo (Insulin Glargine) | ||
| Tresiba (Insulin Degludec) | ||
| Basaglar (Insulin Glargine) | ||
| Bolus or Fast Acting Insulins | NovoRapid/Novolog (Insulin Aspart) | |
| Humalog (Insulin Lispro) | ||
| Apidra (Insulin Glulisine) | ||
| Traditional Human Insulins | Novolin/Actrapid/Insulatard | |
| Humulin | ||
| Insuman | ||
| Biosimilar Insulins | Insulin Glargine Biosimilars | |
| Human Insulin Biosimilars | ||
| Combination drugs | Insulin combinations | NovoMix (Biphasic Insulin Aspart) |
| Ryzodeg (Insulin Degludec and Insulin Aspart) | ||
| Xultophy (Insulin Degludec and Liraglutide) | ||
| Oral Combinations | Janumet (Sitagliptin and Metformin) | |
| Non-Insulin Injectable drugs | GLP-1 receptor agonists | Victoza (Liraglutide) |
| Byetta (Exenatide) | ||
| Bydureon (Exenatide) | ||
| Trulicity (Dulaglutide) | ||
| Lyxumia (Lixisenatide) | ||
| Amylin Analogue | Symlin (Pramlintide) | |
Need A Different Region or Segment?
Customize Now
Key Questions Answered in the Report
How big is the Thailand Diabetes Drugs Market?
The Thailand Diabetes Drugs Market size is expected to reach USD 158.01 million in 2025 and grow at a CAGR of 3.80% to reach USD 190.41 million by 2030.
What is the current Thailand Diabetes Drugs Market size?
In 2025, the Thailand Diabetes Drugs Market size is expected to reach USD 158.01 million.
Who are the key players in Thailand Diabetes Drugs Market?
Eli Lilly, Boehringer Ingelheim, Astrazeneca, Sanofi and NovoNordisk are the major companies operating in the Thailand Diabetes Care Drugs Market.
What years does this Thailand Diabetes Drugs Market cover, and what was the market size in 2024?
In 2024, the Thailand Diabetes Drugs Market size was estimated at USD 152.01 million. The report covers the Thailand Diabetes Drugs Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Thailand Diabetes Drugs Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
